IRIS
MARABOTTO, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.517
Totale 6.517
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.517
Totale 6.517
Salva come PNG Salva come JPEG
Città #
Genova 5.006
Rapallo 830
Genoa 660
Bordighera 21
Totale 6.517
Salva come PNG Salva come JPEG
Nome #
Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers 161
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 156
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. 136
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 133
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 132
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 129
Advancements in the use of manometry and impedance testing for esophageal functional disorders 128
Measurement of oro-caecal transit time by magnetic resonance imaging. 125
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 123
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 122
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 118
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 116
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 114
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 113
A safety review of proton pump inhibitors to treat acid-related digestive diseases 113
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity 110
Proton pump inhibitors: use and misuse in the clinical setting 109
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. 107
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 107
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 107
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 107
Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. 106
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 102
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 101
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 100
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease 98
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 98
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 96
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 96
Optimal management of constipation associated with irritable bowel syndrome. 95
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD 95
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 94
The appropriate use of proton-pump inhibitors 94
The natural history of gastro-esophageal reflux disease: A comprehensive review 92
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 91
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis 90
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 89
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 88
Epidemiology and natural history of gastroesophageal reflux disease 87
Esophageal motility abnormalities in gastroesophageal reflux disease 86
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 84
null 83
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 81
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 80
Updates in the field of non-esophageal gastroesophageal reflux disorder 78
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 77
Effects of bariatric surgery on the esophagus 76
Overweight is a risk factor for both erosive and non-erosive reflux disease. 76
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 75
Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. 74
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 72
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 72
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 68
Nonacid Reflux Is Able to Determine Microscopic Esophagitis in Non-Erosive Reflux Disease (NERD) Patients. 63
The Lyon Consensus: Does it differ from the previous ones? 63
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication 62
Vonoprazan fumarate for the management of acid-related diseases 61
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 61
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 59
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 57
Expression of Epidermal Growth Factor Receptor in patients with gastro-oesophageal reflux disease and in those with Systemic Sclerosis 55
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 49
Presence of basal cell hyperplasia and dilatation of intercellular spaces and their association with baseline impedance values in patients with positive symptom association despite normal acid exposure further supports their role in symptoms generation in NERD 48
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 48
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis 48
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 48
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 45
Pharmacotherapies in eosinophilic esophagitis: state of the art 42
COVID‐19 and liver disease: not all evil comes to harm 39
Diabetes Medications and Risk of Hepatocellular Carcinoma 36
Prevention Strategies for Esophageal Cancer—An Expert Review 35
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 34
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring 33
Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance 32
Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease 32
Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients 31
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 26
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice 25
Latest insights into the hot question of proton pump inhibitor safety – a narrative review 24
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 23
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience 22
Complexity and diversity of gastroesophageal reflux disease phenotypes 22
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach 22
Pharmacological management of gastro-esophageal reflux disease: An update of the state-of-the-art 22
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 21
European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic 19
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 18
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 16
Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply 15
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 14
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 10
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review 9
Eosinophilic esophagitis and biologics 9
Clopidogrel-Induced Eosinophilic Colitis 8
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes? 7
Gastrointestinal Tract Cancers, an Increasing Burden of the Modern Era: Epidemiology and Prevention 7
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 5
How safe are heartburn medications and who should use them? 5
Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD) 4
Food Intolerances, Food Allergies and IBS: Lights and Shadows 4
Totale 6.798
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.768
article - articoli 22.457
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 311
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.536
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019292 0 0 0 0 0 0 0 0 0 0 169 123
2019/20201.958 91 53 76 130 175 243 269 159 212 300 178 72
2020/2021944 43 81 68 118 56 88 41 124 76 105 66 78
2021/20221.036 102 27 67 95 33 104 32 229 66 121 36 124
2022/20231.013 105 100 19 87 177 131 6 85 177 5 110 11
2023/2024538 25 74 8 100 54 124 61 21 32 36 3 0
Totale 6.814